Ziconotide

Identification

Name
Ziconotide
Accession Number
DB06283
Type
Small Molecule
Groups
Approved
Description

Ziconotide (SNX-111; Prialt) is an atypical analgesic agent for the amelioration of severe and chronic pain. Derived from Conus magus (Cone Snail), it is the synthetic form of an ω-conotoxin peptide. In December 2004 the Food and Drug Administration approved ziconotide when delivered as an infusion into the cerebrospinal fluid using an intrathecal pump system.

Synonyms
Not Available
External IDs
SNX-111
Product Ingredients
IngredientUNIICASInChI Key
Ziconotide acetateT2I226K69M914454-03-8Not applicable
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PrialtInjection, solution100 μg/mlIntrathecalEisai Limited2005-02-21Not applicableEu
PrialtInjection, solution100 ug/mLIntrathecalJazz Pharmaceuticals2004-12-28Not applicableUs
PrialtInjection, solution100 μg/mlIntrathecalEisai Limited2005-02-21Not applicableEu
PrialtInjection, solution100 ug/mLIntrathecalJazz Pharmaceuticals2004-12-28Not applicableUs
PrialtInjection, solution100 μg/mlIntrathecalEisai Limited2005-02-21Not applicableEu
PrialtInjection, solution25 ug/mLIntrathecalJazz Pharmaceuticals2004-12-28Not applicableUs
PrialtInjection, solution25 μg/mlIntrathecalEisai Limited2005-02-21Not applicableEu
Categories
UNII
7I64C51O16
CAS number
107452-89-1
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication
Not Available
Structured Indications
Pharmacodynamics
Not Available
Mechanism of action

Ziconotide is a hydrophilic molecule that is freely soluble in water and is practically insoluble in methyl t-butyl ether. Ziconotide acts as a selective N-type voltage-gated calcium channel blocker. This action inhibits the release of pro-nociceptive neurochemicals like glutamate, calcitonin gene-related peptide (CGRP), and substance P in the brain and spinal cord, resulting in pain relief.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Ziconotide.Experimental
2-mercaptobenzothiazoleThe therapeutic efficacy of 2-mercaptobenzothiazole can be increased when used in combination with Ziconotide.Vet Approved
7-NitroindazoleThe risk or severity of adverse effects can be increased when Ziconotide is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Ziconotide is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Ziconotide is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Ziconotide is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Ziconotide.Approved, Illicit
AlfuzosinThe risk or severity of hypotension can be increased when Alfuzosin is combined with Ziconotide.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Ziconotide is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Ziconotide is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ziconotide.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ziconotide.Approved
AmobarbitalThe metabolism of Ziconotide can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe therapeutic efficacy of Amorolfine can be increased when used in combination with Ziconotide.Approved, Investigational
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ziconotide.Approved
AmperozideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Amperozide.Experimental
Amphotericin BThe therapeutic efficacy of Amphotericin B can be increased when used in combination with Ziconotide.Approved, Investigational
AnidulafunginThe therapeutic efficacy of Anidulafungin can be increased when used in combination with Ziconotide.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ziconotide.Approved, Investigational
ArotinololThe risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Ziconotide.Investigational
ArtemetherThe therapeutic efficacy of Artemether can be increased when used in combination with Ziconotide.Approved
ArticaineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Ziconotide.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Ziconotide is combined with Azaperone.Investigational, Vet Approved
AzelastineZiconotide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Ziconotide.Approved
Bafilomycin A1The therapeutic efficacy of Bafilomycin A1 can be increased when used in combination with Ziconotide.Experimental
BarbexacloneThe metabolism of Ziconotide can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Ziconotide can be increased when combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Ziconotide is combined with Benperidol.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Benzocaine.Approved, Investigational
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be increased when used in combination with Ziconotide.Approved, Investigational
Benzyl alcoholThe risk or severity of adverse effects can be increased when Ziconotide is combined with Benzyl alcohol.Approved
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Ziconotide.Approved, Investigational
Brefeldin AThe therapeutic efficacy of Brefeldin A can be increased when used in combination with Ziconotide.Experimental
BrexpiprazoleThe risk or severity of adverse effects can be increased when Ziconotide is combined with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ziconotide.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Ziconotide is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Ziconotide is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Ziconotide.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Ziconotide is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Ziconotide.Investigational
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Ziconotide.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Bupivacaine.Approved, Investigational
BuprenorphineZiconotide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Ziconotide.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ziconotide.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Ziconotide.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Ziconotide is combined with Butamben.Approved
ButenafineThe therapeutic efficacy of Butenafine can be increased when used in combination with Ziconotide.Approved
ButethalThe risk or severity of adverse effects can be increased when Ziconotide is combined with Butethal.Approved, Illicit
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Ziconotide.Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ziconotide.Approved, Illicit, Vet Approved
Calcium AcetateThe therapeutic efficacy of Ziconotide can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Ziconotide can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Ziconotide can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Ziconotide can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Ziconotide can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Ziconotide can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Ziconotide can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Ziconotide can be decreased when used in combination with Calcium lactate.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Ziconotide can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Ziconotide can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Ziconotide can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Ziconotide can be decreased when used in combination with Calcium Phosphate.Approved
CandicidinThe therapeutic efficacy of Candicidin can be increased when used in combination with Ziconotide.Withdrawn
CanertinibThe risk or severity of adverse effects can be increased when Ziconotide is combined with Canertinib.Investigational
Capric acidThe therapeutic efficacy of Capric acid can be increased when used in combination with Ziconotide.Experimental
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Ziconotide.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Ziconotide.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Ziconotide is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Ziconotide.Approved
CarvedilolThe risk or severity of hypotension can be increased when Carvedilol is combined with Ziconotide.Approved, Investigational
CaseinThe therapeutic efficacy of Ziconotide can be decreased when used in combination with Casein.Approved
CaspofunginThe therapeutic efficacy of Caspofungin can be increased when used in combination with Ziconotide.Approved
CeruleninThe therapeutic efficacy of Cerulenin can be increased when used in combination with Ziconotide.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Ziconotide.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Ziconotide is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ziconotide.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Ziconotide is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Chloroprocaine.Approved
ChloroxineThe therapeutic efficacy of Chloroxine can be increased when used in combination with Ziconotide.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ziconotide.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ziconotide.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Ziconotide is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Ziconotide.Approved
CiclopiroxThe therapeutic efficacy of Ciclopirox can be increased when used in combination with Ziconotide.Approved, Investigational
CimetidineThe serum concentration of Ziconotide can be increased when it is combined with Cimetidine.Approved, Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Ziconotide is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Ziconotide.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Ziconotide.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Ziconotide.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Ziconotide is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Ziconotide.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Ziconotide.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Ziconotide.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Ziconotide is combined with Clopenthixol.Experimental
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Ziconotide.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ziconotide.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Clothiapine.Experimental
ClotrimazoleThe therapeutic efficacy of Clotrimazole can be increased when used in combination with Ziconotide.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Ziconotide.Approved
CocaineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Ziconotide.Approved, Illicit
CordycepinThe therapeutic efficacy of Cordycepin can be increased when used in combination with Ziconotide.Investigational
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Ziconotide.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ziconotide.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Ziconotide is combined with Cyclopropane.Experimental
CyclosporineThe therapeutic efficacy of Cyclosporine can be increased when used in combination with Ziconotide.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Ziconotide.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Ziconotide.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Ziconotide is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Ziconotide is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Ziconotide.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Ziconotide.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Ziconotide.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ziconotide.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Ziconotide is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Ziconotide.Approved, Illicit, Investigational, Vet Approved
DichloropheneThe therapeutic efficacy of Dichlorophene can be increased when used in combination with Ziconotide.Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Ziconotide is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Ziconotide.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ziconotide.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Ziconotide.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ziconotide.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ziconotide.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Ziconotide is combined with Doramectin.Vet Approved
DoxazosinThe risk or severity of hypotension can be increased when Doxazosin is combined with Ziconotide.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Ziconotide.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Ziconotide is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Ziconotide is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Ecgonine.Experimental, Illicit
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Ziconotide.Approved
EcopipamThe risk or severity of adverse effects can be increased when Ziconotide is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Ziconotide can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Ziconotide.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Ziconotide is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Ziconotide is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Ziconotide.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Ziconotide is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Ziconotide.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ziconotide.Approved, Investigational
EthanolZiconotide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ziconotide is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ziconotide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Ziconotide.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ziconotide is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ziconotide is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Ziconotide is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Ziconotide is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Ziconotide is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Ziconotide.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Ziconotide.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ziconotide.Approved, Illicit, Investigational, Vet Approved
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Ziconotide.Experimental
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Ziconotide.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Ziconotide.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Ziconotide is combined with Fluanisone.Experimental
FluconazoleThe therapeutic efficacy of Fluconazole can be increased when used in combination with Ziconotide.Approved, Investigational
FlucytosineThe therapeutic efficacy of Flucytosine can be increased when used in combination with Ziconotide.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Ziconotide is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Ziconotide.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Ziconotide is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ziconotide.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ziconotide.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ziconotide.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Ziconotide is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Ziconotide.Approved
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Ziconotide.Experimental
FluvoxamineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Ziconotide.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Ziconotide is combined with Fospropofol.Approved, Illicit, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ziconotide.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Ziconotide is combined with Gabapentin Enacarbil.Approved, Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Ziconotide.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Ziconotide is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Glutethimide.Approved, Illicit
GlyphosateThe therapeutic efficacy of Glyphosate can be increased when used in combination with Ziconotide.Experimental
GriseofulvinThe therapeutic efficacy of Griseofulvin can be increased when used in combination with Ziconotide.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Ziconotide.Approved, Investigational
HachimycinThe therapeutic efficacy of Hachimycin can be increased when used in combination with Ziconotide.Experimental
HalazepamThe risk or severity of adverse effects can be increased when Ziconotide is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ziconotide.Approved
HaloproginThe therapeutic efficacy of Haloprogin can be increased when used in combination with Ziconotide.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Ziconotide is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Ziconotide is combined with Heroin.Approved, Illicit, Investigational
HexetidineThe therapeutic efficacy of Hexetidine can be increased when used in combination with Ziconotide.Approved, Investigational
HexobarbitalThe metabolism of Ziconotide can be increased when combined with Hexobarbital.Approved
HydrocodoneZiconotide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ziconotide.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Ziconotide.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Ziconotide.Approved
IndalpineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Ziconotide is combined with Indiplon.Investigational
IndoraminThe risk or severity of hypotension can be increased when Indoramin is combined with Ziconotide.Withdrawn
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Ziconotide.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Ziconotide.Approved, Vet Approved
ItraconazoleThe therapeutic efficacy of Itraconazole can be increased when used in combination with Ziconotide.Approved, Investigational
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Ziconotide.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ziconotide is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ziconotide is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe therapeutic efficacy of Ketoconazole can be increased when used in combination with Ziconotide.Approved, Investigational
LabetalolThe risk or severity of hypotension can be increased when Labetalol is combined with Ziconotide.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ziconotide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Ziconotide.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Ziconotide.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Ziconotide.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Ziconotide is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Ziconotide is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ziconotide.Approved
LidocaineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Lidocaine.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Ziconotide is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Ziconotide is combined with Lofentanil.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Ziconotide is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Ziconotide.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ziconotide.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Ziconotide is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Ziconotide.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ziconotide.Approved, Investigational
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Ziconotide is combined with Magnesium Hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Ziconotide is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Ziconotide is combined with Magnesium salicylate.Approved
Magnesium sulfateThe therapeutic efficacy of Ziconotide can be increased when used in combination with Magnesium Sulfate.Approved, Investigational, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ziconotide.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Ziconotide is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Ziconotide.Approved
MedazepamThe risk or severity of adverse effects can be increased when Ziconotide is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Ziconotide is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Ziconotide is combined with Melperone.Approved, Investigational
MepartricinThe therapeutic efficacy of Mepartricin can be increased when used in combination with Ziconotide.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ziconotide.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Ziconotide is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Ziconotide.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Ziconotide.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Ziconotide is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Ziconotide is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Ziconotide is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ziconotide.Approved, Vet Approved
MethohexitalThe metabolism of Ziconotide can be increased when combined with Methohexital.Approved
MethotrimeprazineZiconotide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Ziconotide is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Ziconotide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Methylecgonine.Experimental
MethylphenobarbitalThe metabolism of Ziconotide can be increased when combined with Methylphenobarbital.Approved
MetyrosineZiconotide may increase the sedative activities of Metyrosine.Approved
MevastatinThe therapeutic efficacy of Mevastatin can be increased when used in combination with Ziconotide.Experimental
MicafunginThe therapeutic efficacy of Micafungin can be increased when used in combination with Ziconotide.Approved, Investigational
MiconazoleThe therapeutic efficacy of Miconazole can be increased when used in combination with Ziconotide.Approved, Investigational, Vet Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Ziconotide.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Ziconotide is combined with Milnacipran.Approved, Investigational
MiltefosineThe therapeutic efficacy of Miltefosine can be increased when used in combination with Ziconotide.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.Approved, Investigational
MirtazapineZiconotide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Ziconotide is combined with Molindone.Approved
MonensinThe therapeutic efficacy of Monensin can be increased when used in combination with Ziconotide.Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Ziconotide.Approved, Investigational
MyxothiazolThe therapeutic efficacy of Myxothiazol can be increased when used in combination with Ziconotide.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.Approved, Investigational
NafcillinThe therapeutic efficacy of Ziconotide can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftifineThe therapeutic efficacy of Naftifine can be increased when used in combination with Ziconotide.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ziconotide.Approved
NatamycinThe therapeutic efficacy of Natamycin can be increased when used in combination with Ziconotide.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Ziconotide is combined with Nefazodone.Approved, Withdrawn
NifuratelThe therapeutic efficacy of Nifuratel can be increased when used in combination with Ziconotide.Experimental
Nikkomycin ZThe therapeutic efficacy of Nikkomycin Z can be increased when used in combination with Ziconotide.Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ziconotide.Approved
NitroprussideZiconotide may increase the hypotensive activities of Nitroprusside.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Ziconotide.Approved, Vet Approved
NitroxolineThe therapeutic efficacy of Nitroxoline can be increased when used in combination with Ziconotide.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Ziconotide is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Ziconotide is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ziconotide.Approved
NystatinThe therapeutic efficacy of Nystatin can be increased when used in combination with Ziconotide.Approved, Vet Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ziconotide.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ziconotide.Approved
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Ziconotide.Experimental
OndansetronThe risk or severity of adverse effects can be increased when Ziconotide is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Ziconotide is combined with Opium.Approved, Illicit
OrphenadrineZiconotide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Ziconotide is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ziconotide.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Oxethazaine.Approved, Investigational
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Ziconotide.Approved
OxprenololThe risk or severity of adverse effects can be increased when Ziconotide is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ziconotide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ziconotide.Approved, Investigational, Vet Approved
PafuramidineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Ziconotide.Investigational
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ziconotide.Approved
ParaldehydeZiconotide may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Ziconotide is combined with Penfluridol.Experimental
PentamidineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Ziconotide.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ziconotide.Approved, Vet Approved
PentobarbitalThe metabolism of Ziconotide can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.Approved
PerazineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Perazine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Ziconotide is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ziconotide.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ziconotide.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Ziconotide is combined with Phenibut.Experimental
PhenobarbitalThe metabolism of Ziconotide can be increased when combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Ziconotide is combined with Phenoxyethanol.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Ziconotide.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Ziconotide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Ziconotide is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Ziconotide.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Piritramide.Approved, Investigational
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Ziconotide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Pomalidomide.Approved
PosaconazoleThe therapeutic efficacy of Posaconazole can be increased when used in combination with Ziconotide.Approved, Investigational, Vet Approved
PramipexoleZiconotide may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Ziconotide is combined with Prazepam.Approved, Illicit
PrazosinThe risk or severity of hypotension can be increased when Prazosin is combined with Ziconotide.Approved
PregabalinThe therapeutic efficacy of Ziconotide can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Prilocaine.Approved
PrimidoneThe metabolism of Ziconotide can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ziconotide.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Ziconotide.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Ziconotide.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Ziconotide is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Ziconotide.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ziconotide.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Ziconotide is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Ziconotide is combined with PSD502.Investigational
PyrrolnitrinThe therapeutic efficacy of Pyrrolnitrin can be increased when used in combination with Ziconotide.Experimental
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Ziconotide.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ziconotide.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Raclopride.Investigational
RadicicolThe therapeutic efficacy of Radicicol can be increased when used in combination with Ziconotide.Experimental
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Ziconotide.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ziconotide.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Ziconotide.Approved, Investigational
RifabutinThe risk or severity of hypotension can be increased when Rifabutin is combined with Ziconotide.Approved, Investigational
RifampicinThe risk or severity of hypotension can be increased when Rifampicin is combined with Ziconotide.Approved
RifapentineThe risk or severity of hypotension can be increased when Rifapentine is combined with Ziconotide.Approved, Investigational
RifaximinThe risk or severity of hypotension can be increased when Rifaximin is combined with Ziconotide.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Ziconotide.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ziconotide is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Romifidine.Vet Approved
RopiniroleZiconotide may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Ropivacaine.Approved
RotigotineZiconotide may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Ziconotide.Approved
Salicylhydroxamic AcidThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Ziconotide.Experimental
Salicylic acidThe therapeutic efficacy of Salicylic acid can be increased when used in combination with Ziconotide.Approved, Investigational, Vet Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ziconotide.Approved, Investigational
SecobarbitalThe metabolism of Ziconotide can be increased when combined with Secobarbital.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Ziconotide is combined with Sepranolone.Investigational
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Ziconotide.Approved, Investigational
SertindoleThe risk or severity of adverse effects can be increased when Ziconotide is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ziconotide.Approved, Vet Approved
SilodosinThe risk or severity of hypotension can be increased when Silodosin is combined with Ziconotide.Approved
SinefunginThe therapeutic efficacy of Sinefungin can be increased when used in combination with Ziconotide.Experimental
SirolimusThe therapeutic efficacy of Sirolimus can be increased when used in combination with Ziconotide.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.Approved
StiripentolThe risk or severity of adverse effects can be increased when Ziconotide is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ziconotide.Approved, Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Ziconotide.Approved
SulpirideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Sultopride.Experimental
SuvorexantZiconotide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Ziconotide.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Ziconotide is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Ziconotide is combined with Tasimelteon.Approved, Investigational
TavaboroleThe therapeutic efficacy of Tavaborole can be increased when used in combination with Ziconotide.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Ziconotide.Approved, Investigational
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Ziconotide.Approved
TerbinafineThe therapeutic efficacy of Terbinafine can be increased when used in combination with Ziconotide.Approved, Investigational, Vet Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Ziconotide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Ziconotide.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Ziconotide is combined with Tetrodotoxin.Investigational
ThalidomideZiconotide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe metabolism of Ziconotide can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Ziconotide can be increased when combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ziconotide.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ziconotide.Approved
ThymolThe therapeutic efficacy of Thymol can be increased when used in combination with Ziconotide.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Ziconotide.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Tilidine.Experimental
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Ziconotide.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Ziconotide.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Ziconotide.Approved, Withdrawn
TolciclateThe therapeutic efficacy of Tolciclate can be increased when used in combination with Ziconotide.Experimental
TolnaftateThe therapeutic efficacy of Tolnaftate can be increased when used in combination with Ziconotide.Approved, Investigational, Vet Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Ziconotide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Ziconotide.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Ziconotide is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Ziconotide.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Ziconotide is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Ziconotide is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ziconotide.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Ziconotide is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Triflupromazine.Approved, Vet Approved
TrimazosinThe risk or severity of hypotension can be increased when Trimazosin is combined with Ziconotide.Experimental
TrimetrexateThe therapeutic efficacy of Trimetrexate can be increased when used in combination with Ziconotide.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ziconotide.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Ziconotide.Approved
UrapidilThe risk or severity of hypotension can be increased when Urapidil is combined with Ziconotide.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Ziconotide is combined with Valproic Acid.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Ziconotide.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Ziconotide is combined with Vinyl ether.Experimental
VoriconazoleThe therapeutic efficacy of Voriconazole can be increased when used in combination with Ziconotide.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Vortioxetine.Approved, Investigational
XenonThe risk or severity of adverse effects can be increased when Ziconotide is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ziconotide.Approved, Illicit, Investigational
ZimelidineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Ziconotide.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Ziconotide is combined with Zolazepam.Vet Approved
ZolpidemZiconotide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Ziconotide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Ziconotide.Approved
ZotepineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ziconotide.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Skov MJ, Beck JC, de Kater AW, Shopp GM: Nonclinical safety of ziconotide: an intrathecal analgesic of a new pharmaceutical class. Int J Toxicol. 2007 Sep-Oct;26(5):411-21. [PubMed:17963128]
  2. McIntosh M, Cruz LJ, Hunkapiller MW, Gray WR, Olivera BM: Isolation and structure of a peptide toxin from the marine snail Conus magus. Arch Biochem Biophys. 1982 Oct 1;218(1):329-34. [PubMed:7149738]
  3. Miljanich GP: Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. Curr Med Chem. 2004 Dec;11(23):3029-40. [PubMed:15578997]
  4. McGivern JG: Ziconotide: a review of its pharmacology and use in the treatment of pain. Neuropsychiatr Dis Treat. 2007 Feb;3(1):69-85. [PubMed:19300539]
External Links
KEGG Drug
D06363
PubChem Substance
347910345
ChEMBL
CHEMBL2103752
Wikipedia
Ziconotide
ATC Codes
N02BG08 — Ziconotide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Active Not RecruitingTreatmentCancers / Pain / Pain, Intractable / Pain, Neuropathic1
2CompletedTreatmentCancers / Human Immunodeficiency Virus (HIV) Infections / Pain1
3CompletedTreatmentPain2
4CompletedNot AvailablePeripheral Neuropathy1
4WithdrawnTreatmentPainful Myelopathy / Painful Neuropathy1
Not AvailableCompletedNot AvailablePatients With Severe Chronic Pain1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, solutionIntrathecal100 μg/ml
Injection, solutionIntrathecal100 ug/mL
Injection, solutionIntrathecal25 ug/mL
Injection, solutionIntrathecal25 μg/ml
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5859186No1994-12-302011-12-30Us
US5364842No1996-12-302016-12-30Us
US8653033No2004-10-012024-10-01Us
US8765680No2004-10-012024-10-01Us
US9707270No2004-10-012024-10-01Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on March 19, 2008 10:21 / Updated on February 03, 2018 16:39